Skip to main content

Table 2 Effects of nrf2 genotype on changes in mRNA levels of phase 2 and antioxidative enzymes following treatment with D3T

From: Role of Transcription Factor Nrf2 in the Induction of Hepatic Phase 2 and Antioxidative Enzymes in vivo by the Cancer Chemoprotective Agent, 3H-1, 2-Dithiole-3-thione

Nrf2 Genotype

+/+

−/−

+/+

−/−

Enzyme

Constitutive Levels

Inducible Levels

GST Ya

1

0.63

6.38a

0.79

GST Yp

1

0.28

4.93a

0.66b

GST Yb

1

1.26

2.63a

0.87

GST Yc

1

0.75

1.07

0.29b

NQO1

1

1.11

5.95a

0.67

UGT1A6

1

0.99

3.63a

0.24b

mEH

1

0.52

4.02a

1.13

γGCSr

1

1.29

2.84a

1.40

AFAR

1

0.73

1.13

0.15b

HO-1

1

1.66

5.89a

0.72

Ferritin Light

1

0.94

1.53

2.45b

Ferritin Heavy

1

0.58

1.13

2.08b

MnSOD

1

1.31

2.02a

0.05b

Catalase

1

1.08

1.40

0.39b

  1. Relative mRNA levels were analyzed after D3T treatment in nrf2 wild-type and mutant type mouse liver. GST Ya, Yp, Yb, Yc, mEH, FH, and FL mRNA were detected using northern blot hybridization and NQO1, UGT1A6, γGCSr, HO-1, AFAR, MnSOD, and CAT levels were detected using RT-PCR. Values are the means of determinations done on three mice per genotype. Levels of RNA for each gene were normliazed to albumin mRNA levels and expressed as a ratio over vehicle-treated wild-type control. Transcript levels were measured 24 hr after treatment with D3T for all genes except HO-1, which was measured at 6 hr.
  2. ap, 0.05, compared to vehicle-treated 2/1.
  3. bp, 0.05, compared to vehicle-treated 2/2 group.